H.C. Wainwright analyst Raghuram Selvaraju views the selloff in Acorda Therapeutics yesterday after a district court upheld the decision to invalidate Ampyra patents as overdone. Acorda "still possesses an ace up its sleeve," namely the potential near-term launch of its most advanced clinical-stage candidate, Inbrija, for Parkinson's disease. The analyst feels that Acorda could wind up being an acquisition target despite the failure to maintain patent protection on Ampyra because of interest in Inbrija. He reiterates a Buy rating on the shares with a $31 price target.